Compared to individuals with a normal weight (BMI 18.5 to <25 kg/m²), those with displayed a heightened risk of cardiac tamponade (relative risk [RR] 142; 95% confidence interval [CI] 103-195).
The requested JSON schema format contains a list of sentences. Factors associated with a higher chance of cardiac tamponade involved age 75 and above, female sex, as well as a prior history of heart failure, hypertension, diabetes, and dialysis treatment.
A nationwide investigation into AF ablation procedures found that patients with lower-than-average weight had an elevated independent risk of cardiac tamponade. Clinicians should meticulously evaluate the heightened risk of cardiac tamponade in underweight individuals and adopt preventive strategies.
Ablation procedures on AF patients within a comprehensive nationwide database showcased an independent association between underweight status and a higher risk of cardiac tamponade. For individuals with low body weight, a higher probability of cardiac tamponade exists; clinicians should consequently take appropriate precautions.
Frequent premature ventricular complexes (PVCs) can be a cause of a reversible cardiomyopathy, concentrating its impact on the left ventricle.
We sought to understand the connection between frequent premature ventricular complexes (PVCs) and the function of the right ventricle (RV).
A longitudinal investigation using cardiac magnetic resonance (CMR) was conducted on 47 patients, involving examinations before and after the elimination of their frequent premature ventricular complexes (PVCs) through ablation.
Patients with right ventricular cardiomyopathy (ejection fraction (EF) less than 0.45) showed a statistically significant increase in the frequency of premature ventricular contractions (PVCs) compared to patients with preserved right ventricular function (23% ± 11% versus 15% ± 11%, P=0.003). Patients with left ventricular cardiomyopathy (ejection fraction below 0.50) demonstrated a more frequent occurrence of premature ventricular contractions (PVCs) than those without reduced left ventricular function (23% ± 10% vs 14% ± 12%, P=0.0003). The prevalence of LV dysfunction in the study was 45%, affecting 21 patients. Left ventricular (LV) dysfunction was observed in a cohort of patients, where 15 (32%) patients displayed biventricular dysfunction and 6 (13%) patients had isolated left ventricular dysfunction. RV dysfunction was observed in 19 (40%) patients. In 4 of these patients (9%) with RV dysfunction, the dysfunction was the only observable abnormality. Post-ablation, a cardiac magnetic resonance scan was repeated 13 years later, again. Successful ablation was associated with a demonstrable improvement in right ventricular (RV) function, but in the group without successful ablation, RV function remained unchanged (pre-ablation RVEF 0.45 ± 0.09 and 0.46 ± 0.07; post-ablation RVEF 0.52 ± 0.09 and 0.48 ± 0.04; p < 0.001 vs. p = 0.14, respectively).
In cases of frequent PVCs, right ventricular cardiomyopathy develops, exhibiting a pattern akin to left ventricular cardiomyopathy, and effective ablation procedures can reverse this condition.
Premature ventricular contractions (PVCs), occurring frequently, can cause right ventricular cardiomyopathy, a condition that aligns with the progression of left ventricular cardiomyopathy, and this condition can be reversed via successful ablation.
The mechanisms underpinning the shifts in proarrhythmic substrates and the development of malignant ventricular arrhythmias associated with premature ventricular contraction-induced cardiomyopathy (PVCCM) are still unknown.
The electrophysiological mechanism by which high-load PVCs produce malignant arrhythmia was the focus of this study.
Pacing with 50% paced PVCs from the right ventricular apex (PVCCM group, n=6) was applied for twelve weeks to thirteen pigs. A control group (n=7) did not receive any pacing. Cardiac function was assessed biweekly using echocardiography. Monthly computed tomography scans and electrophysiological examinations were conducted to track and assess evolving cardiac structure and arrhythmogenic substrate.
Following 12 weeks of PVC stimulation, the PVCCM group exhibited significantly reduced cardiac function and ventricular enlargement compared to the control group (P<0.0001). A low-voltage zone (941 155cm) was observed during the electrophysiological examination, co-occurring with a dispersion of the ventricular effective refractory period (0071 0008).
At week eight after the pacing, a marked 333% increase in the inducibility of malignant ventricular arrhythmia occurred in the PVCCM group, which was significantly different from the control group (P < 0.001). This rise in inducibility then moderated over the subsequent period. In addition, the spatial distribution of the low-voltage zone displayed notable heterogeneity, especially within the right ventricle's anterior wall, coupled with delayed activation during sinus rhythm (67–13 milliseconds). Consistently, and in a statistically significant manner (P<0.0001), the PVCCM group showed a marked increase in ventricular fibrosis- and expression-related proteins, primarily within the right ventricle. In addition, proteomic analysis definitively indicated the spatial pattern of fibrotic changes, uniquely evident in the PVCCM group.
Significant temporal and spatial alterations in proarrhythmic substrates may arise from high-burden PVCs, potentially stemming from the calcium signaling increase prompted by asynchronous activation.
High-burden PVCs demonstrably modify both the temporal and spatial characteristics of proarrhythmic substrates, a modification possibly attributed to asynchronous activation and resultant calcium signaling escalation.
For patients suffering from difficult-to-treat ventricular arrhythmias (VAs), neuromodulation is becoming a more widely acknowledged therapeutic avenue. Percutaneous stellate ganglion blockade (SGB), transcutaneous magnetic stimulation (TcMS), and surgical cardiac sympathetic denervation (CSD) constitute a variety of interventions used in this circumstance.
This investigation aimed to delineate current applications and consequences of these neuromodulation strategies for individuals experiencing treatment-resistant VA.
In a retrospective cohort study, all patients at the University of Pennsylvania Hospital with antiarrhythmic drug (AAD)-refractory ventricular arrhythmias (VA) treated with SGB, TcMS, or CSD between 2019 and 2021 were examined.
A total of 34 patients, whose ages ranged from 61 to 75 years, presented with 15 polymorphic visual impairments (VAs) and were refractory to 18 of 80 available anti-AADs, meeting the inclusion criteria. A breakdown of the procedures reveals that 11 patients (32%) underwent SGB, 19 (56%) received TcMS, and CSD was applied to 7 (21%). Neuromodulation's application was strongly associated with a decrease in the number of sustained Visual Acuity episodes. Specifically, the 24 hours prior to the neuromodulation strategy saw seven episodes (interquartile range 4-12), while the subsequent 24 hours displayed a drastic reduction to zero episodes (interquartile range 0-1). This difference was statistically significant (P < 0.0001). Throughout the 12 years and 11 months of follow-up, 21 (62%) patients experienced a return of vascular anomalies (VAs). The median time until these recurrences occurred was 3 days, with an interquartile range (IQR) of 1 to 25 days. The outcomes associated with monomorphic and polymorphic vascular anomalies were consistently similar. Among patients who experienced an acute myocardial infarction within 30 days prior to neuromodulation, there was a reduction in the burden of vascular events (VAs) from an initial amount of 11 [IQR 7-12] episodes to 0 episodes during the 24 hours after the treatment.
Autonomic neuromodulation, using SGB, TcMS, or CSD, is a safe therapeutic approach for patients with AAD-refractory vascular arrhythmias, leading to a significant acute improvement in vascular arrhythmias, while recurrent arrhythmias are common, and not all patients achieve a reduction in the overall arrhythmia burden.
Applying SGB, TcMS, or CSD autonomic neuromodulation strategies to AAD-refractory VA patients shows safety, yielding substantial immediate improvements in VA, although recurrent arrhythmias are prevalent, and a reduction in arrhythmia burden is not universally observed.
A frequent comorbidity for patients with heart failure and preserved ejection fraction (HFpEF) is atrial fibrillation (AF). To the present day, the therapeutic arsenal for atrial fibrillation in cases of HFpEF has been primarily composed of anti-arrhythmic drugs and ablation techniques. The present study assessed the impact of immortalized cardiosphere-derived extracellular vesicles (imCDCevs) on rats experiencing heart failure with preserved ejection fraction (HFpEF).
An investigation into the mechanisms of AF within the context of HFpEF was undertaken, alongside an exploration of imCDCevs' potential therapeutic role in HFpEF-related atrial fibrillation.
Following a seven-week regimen of a high-salt diet, Dahl salt-sensitive rats were categorized into groups, one receiving imCDCevs (n=18) intravenously and the other vehicle (n=14), to examine the development of HFpEF. Control animals, consisting of rats on a standard sodium diet, numbered 26. A comprehensive characterization of atrial remodeling was performed via the application of functional and molecular methods.
Animals with confirmed HFpEF exhibited a substantially increased capability for atrial fibrillation induction (84%) in contrast to the control group (15%). Compared to control animals, HFpEF animals exhibited a prolonged action potential duration, slowed conduction velocity (characterized by connexin 43 lateralization), and fibrotic remodeling specifically within the left atrium. ImCDCevs successfully reversed adverse electrical remodeling, re-establishing control over action potential duration and reorganizing connexin 43, thereby reducing the inducibility of atrial fibrillation by 33%. akt signal ImCDCevs treatment led to a considerable attenuation of fibrosis, inflammation, and oxidative stress, which are pivotal pathological factors in atrial fibrillation.akt signal
Top comments (0)